NICE Rejects Novartis’ Xolair In Harbinger Of Cost Reevaluation Process

Draft guidance from NICE concludes that Novartis’ asthma drug Xolair, which was previously viewed as cost-effective, is no longer worth the expense based on new independent economic modeling and mortality data. The re-evaluation process is spreading through Europe as governments move to restrain costs, and that may spell trouble for manufacturers.